Annie Onanong Chivatakarn
About Annie Onanong Chivatakarn
Annie Onanong Chivatakarn is a Principal Scientist at Tessera Therapeutics, specializing in RNA therapeutics and genetic medicines for rare diseases. She has extensive research experience, including previous roles at Wave Life Sciences and the Salk Institute for Biological Studies.
Work at Tessera Therapeutics
Annie Onanong Chivatakarn serves as a Principal Scientist at Tessera Therapeutics. She has held this position since 2021 in Cambridge, Massachusetts. In her role, she focuses on advancing the development of genetic medicines, particularly targeting the rare disease community. Her work contributes to the company's mission of creating innovative therapeutic solutions.
Previous Experience at Wave Life Sciences
Chivatakarn worked at Wave Life Sciences from 2018 to 2021, where she held two positions. Initially, she served as a Scientist for two years before being promoted to Senior Scientist in 2020. During her tenure in Cambridge, Massachusetts, she contributed to the development of RNA therapeutics, enhancing her expertise in genetic medicine.
Background in Research and Education
Chivatakarn has a robust academic background in Neuroscience. She earned her Bachelor of Science (B.S.) from the University of California, Los Angeles, and later obtained her Doctor of Philosophy (Ph.D.) from the University of Rochester. Her education laid the foundation for her extensive research career, which includes significant experience in central nervous system, muscle, and liver target areas.
Experience at Salk Institute for Biological Studies
Before her roles at Wave Life Sciences and Tessera Therapeutics, Chivatakarn spent ten years at the Salk Institute for Biological Studies as a Senior Research Scientist from 2008 to 2018. In this capacity, she focused on various research initiatives, further developing her expertise in genetic medicine and therapeutic development.
Passion for Advancing Genetic Medicines
Chivatakarn is dedicated to advancing genetic medicines to benefit patients with rare diseases. Her work reflects a commitment to addressing unmet medical needs within this community, leveraging her extensive research background and expertise in RNA therapeutics.